Related Experiment Video
Updated: Jun 21, 2026

Captive Maintenance and Venom Extraction of Tityus serrulatus (Brazilian Yellow Scorpion) for Antivenom Production
Published on: October 6, 2023
Antisnake venom production crisis--who told us it was uneconomic and unsustainable?
Ian D Simpson1, Ingrid M Jacobsen
1Pakistan Medical Research Council, Islamabad, Pakistan. iandsimpson@gmail.com
Abstract:
The world of antisnake venom production is currently a gloomy place to visit. It is described as being in crisis, characterized by shortages, producers leaving the market, high prices, and unsustainability. It has been reduced to a pauper-like status, doomed to relying on charitable handouts for resolution. The worrying aspect of this is that little work has been done to establish the true economics and return on antisnake venom if provided by private companies. Fortunately, it is amenable to economic analysis, and in this manner, a rational approach to further development and distribution can be obtained. This article proposes a model antisnake venom (ASV) production unit and shows the likely economics and return based on the production of various volumes of ASV. It estimates the costs for the key components of the unit, which are production equipment and staffing. A profit and loss account and balance sheet are constructed for the unit, and the effects of ASV volume and neutralizing titres are demonstrated. It is our contention that ASV production can be sustained at affordable prices in the developing world. We recommend that any solution to the ASV shortage must take into account the most cost efficient method(s) of production.
More Related Videos
12:16High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli
Published on: July 30, 2014
10:25Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
Published on: November 3, 2014
Related Concept Videos
Production of Biopesticides
Threats to Biodiversity
Vaccine Production